|
APONTIS PHARMA AG / Key word(s): Personnel APONTIS PHARMA AG: CEO Karlheinz Gast resigns from office for personal reasons 10-Jul-2023 / 13:45 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014 APONTIS PHARMA AG: CEO Karlheinz Gast resigns from office for personal reasons Monheim am Rhein, 10 July 2023. The Chief Executive Officer (CEO) of APONTIS PHARMA AG (“APONTIS PHARMA” or “Company“, Ticker APPH / ISIN DE000A3CMGM5), Karlheinz Gast, has informed the Supervisory Board today that he is resigning from his office for personal reasons with immediate effect and that he is leaving the Executive Board. The Supervisory Board received and accepted Mr. Gast’s resignation at its extraordinary meeting today. The service agreement with Mr. Gast will be canceled by mutual agreement. At the same time, the Supervisory Board appointed Bruno Wohlschlegel as a member of the Executive Board and as CEO for a period of 2 years with an effective date 1 September 2023. Until then, Executive Board member Thomas Milz will manage the Company alone. APONTIS PHARMA AG Investor Relations APONTIS PHARMA press contact CROSS ALLIANCE End of Inside Information 10-Jul-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Biotech’s road to recovery with 46% increase in Q1 venture funding
Private biotech venture financing saw a 46% increase in total deal value in the first quarter (Q1) of 2024 compared to Q4 2023, according to
May 28, 2024